The WAG/Rij @entity35 model for nonconvulsive XXXX : involvement of nonNMDA receptors.

@entity1 @entity410 @entity4176 @entity140 @entity6191 @entity2048 @entity35 @entity302 @entity5373
The involvement of @entity140 and @entity4176 receptors in @entity6191 was studied by intracerebroventricular injections of @entity140 , GDEE, @entity4176 and @entity5373 in WAG/Rij @entity35 . The WAG/Rij @entity35 is recognized as an animal model for @entity1 @entity2048 . EEG registrations showed that @entity140 (0.1 pmol/5 microliters; 1 pmol/5 microliters; 10 pmol/5 microliters) dose-dependently increased the nonconvulsive @entity2048 while GDEE (0.2 mumol/5 microliters; 1 mumol/5 microliters; 5 umol/5 microliters) caused a dose-dependent decrease. All effects of GDEE could be blocked by an inactive @entity140 dosage. @entity4176 (0.01 nmol/5 microliters; 0.1 nmol/5 microliters; 0.15 nmol/5 microliters) had no effects on the @entity6191 but induced @entity410 in the two highest dosages. @entity5373 (50 nmol/5 microliters; 100 nmol/5 microliters; 500 nmol/5 microliters) decreased dose-dependently the incidence of @entity6191 . The effect of @entity5373 could be blocked by a nonconvulsive dosage of @entity4176 . These results show that the @entity140 and @entity4176 receptor appear to be involved in @entity6191 . Furthermore, blockage of these two receptor subtypes led to an antiepileptic effect without inducing behavioural alterations. Therefore, selective @entity140 and @entity4176 receptor antagonists might be potent anti- @entity302 .
